
    
      The standard or usual treatment for this disease is a chemotherapy drug called docetaxel,
      given by intravenous every 3 weeks, for up to 12 treatments.

      177Lu-PSMA-617 is a new type of therapy for prostate cancer. Laboratory tests show that it
      may help slow the growth of prostate cancer. 177Lu-PSMA-617 has been shown to shrink tumours
      in animals and has been studied in limited numbers of men with prostate cancer and seems
      promising but it is not clear if it can offer better control of prostate cancer compared to
      docetaxel chemotherapy .
    
  